Top

World Journal of Urology

Published in:

01-10-2020 | Multiple Sclerosis | Invited Review

The use of mirabegron in neurogenic bladder: a systematic review

Authors: Elie El Helou, Chris Labaki, Roy Chebel, Jeanine El Helou, Georges Abi Tayeh, Georges Jalkh, Elie Nemr

Published in: World Journal of Urology | Issue 10/2020

Abstract

Purpose

To evaluate the use of mirabegron in patients with neurogenic bladder.

Methods

A systematic review of the literature was conducted using four databases (Medline via PubMed, Scopus, Cochrane, and EMBASE). Articles evaluating mirabegron in neurogenic bladder patients were collected, and assessment of the drug’s efficacy was reviewed according to clinical and urodynamic parameters.

Results

Seven studies were selected and a total of 302 patients with NB were evaluated, ranging from 15 to 66 patients per study. All of the patients had received antimuscarinics as a previous treatment modality. Mirabegron was used as a second-line treatment after antimuscarinics lacked efficacy or caused adverse effects. The duration of the treatments ranged from 4 to 12 weeks. Reported in two studies each, bladder compliance and maximal cystometric capacity were the most commonly improved urodynamic parameters. In the majority of the studies, positive outcomes were reported for clinical scores. Additionally, analysis of the IPSS subscores revealed an improvement of storage symptoms as opposed to voiding symptoms. In all of the studies, mirabegron was well tolerated.

Conclusion

Mirabegron appears to be an effective treatment in the management of neurogenic bladder unresponsive to antimuscarinics, particularly in patients presenting with storage symptoms. There is still no evidence concerning the use of mirabegron as a first-line therapy for neurogenic bladder.

Manack A, Motsko SP, Haag-Molkenteller C et al (2013) Epidemiology and Healthcare Utilization of Neurogenic Bladder Patients in a US Claims Database. Neurourol Urodyn 32:215–223. https://doi.org/10.1002/nauCrossRef

Oh SJ, Shin HI, Paik NJ et al (2006) Depressive symptoms of patients using clean intermittent catheterization for neurogenic bladder secondary to spinal cord injury. Spinal Cord 44:757–762. https://doi.org/10.1038/sj.sc.3101903CrossRefPubMed

Oh SJ, Ku JH, Jeon HG et al (2004) Health-related quality of life of patients using clean intermittent catheterization for neurogenic bladder secondary to spinal cord injury. Urology. https://doi.org/10.1016/j.urology.2004.09.032CrossRefPubMed

Lawerson A, Wyndaele JJ, Vlachonikolis I et al (2001) Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology 20:138–143CrossRef

Ginsberg D (2013) The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care 19:191–196

Cameron AP (2010) Pharmacologic therapy for the neurogenic bladder. Urol Clin NA 37:495–506. https://doi.org/10.1016/j.ucl.2010.06.004CrossRef

Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M (2012) Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol 62:816–830. https://doi.org/10.1016/j.eururo.2012.02.036CrossRefPubMed

Vouri SM, Kebodeaux CD, Stranges PM, Teshome BF (2017) Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis. Arch Gerontol Geriatr 69:77–96. https://doi.org/10.1016/j.archger.2016.11.006CrossRefPubMed

Kim A, Lee KS, Jung R et al (2017) Health related quality of life in patients with side-effects after antimuscarinic treatment for overactive bladder. LUTS Low Urin Tract Symptoms 9:171–175. https://doi.org/10.1111/luts.12132CrossRefPubMed

10.

Engeler DS, Meyer D, Abt D et al (2015) Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series. BMC Urol 15:4–9. https://doi.org/10.1186/s12894-015-0102-xCrossRef

11.

Herschorn S, Gajewski J, Ethans K et al (2011) Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a Randomized, double-blind trial. J Urol 185:2229–2235. https://doi.org/10.1016/j.juro.2011.02.004CrossRefPubMed

12.

Korstanje C, Suzuki M, Yuno K et al (2017) Translational science approach for assessment of cardiovascular effects and proarrhythmogenic potential of the beta-3 adrenergic agonist mirabegron. J Pharmacol Toxicol Methods 87:74–81. https://doi.org/10.1016/j.vascn.2017.04.008CrossRefPubMed

13.

Rosa GM, Baccino D, Valbusa A et al (2018) Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder. Expert Opin Drug Saf 17:487–497. https://doi.org/10.1080/14740338.2018.1453496CrossRefPubMed

14.

Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. https://doi.org/10.1186/2046-4053-4-1CrossRefPubMedPubMedCentral

15.

Park JS, Lee YS, Lee CN et al (2018) Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. World J Urol. https://doi.org/10.1007/s00345-018-2576-0CrossRefPubMed

16.

Zachariou A, Filiponi M, Baltogiannis D et al (2017) Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. Can J Urol 24:9107–9113PubMed

17.

Welk B, Hickling D, McKibbon M et al (2018) A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn 37:2810–2817. https://doi.org/10.1002/nau.23774CrossRefPubMed

18.

Wöllner J, Pannek J (2016) Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord 54:78–82. https://doi.org/10.1038/sc.2015.195CrossRefPubMed

19.

Krhut J, Borovička V, Bílková K et al (2018) Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn 37:2226–2233. https://doi.org/10.1002/nau.23566CrossRefPubMed

20.

Chen SF, Kuo HC (2019) Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. LUTS Low Urin Tract Symptoms 11:O53–O58. https://doi.org/10.1111/luts.12215CrossRefPubMed

21.

Matsuo T, Miyata Y, Nakamura T et al (2019) Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy. LUTS Low Urin Tract Symptoms 11:O65–O70. https://doi.org/10.1111/luts.12218CrossRefPubMed

22.

Robinson D, Thiagamoorthy G, Cardozo L (2016) A drug safety evaluation of mirabegron in the management of overactive bladder. Expert Opin Drug Saf 15:689–696. https://doi.org/10.1517/14740338.2016.1165663CrossRefPubMed

Title: The use of mirabegron in neurogenic bladder: a systematic review
Authors: Elie El Helou
Chris Labaki
Roy Chebel
Jeanine El Helou
Georges Abi Tayeh
Georges Jalkh
Elie Nemr
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Keywords: Multiple Sclerosis
Neurogenic Bladder
Overactive Bladder
Published in: World Journal of Urology / Issue 10/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-03040-x

At a glance: The STEP trials

Springer Medicine

The use of mirabegron in neurogenic bladder: a systematic review

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2020

The era of the digital natives is approaching: Insights into online peer-to-peer support for persons affected by prostate cancer

Robotic-assisted kidney transplant: a single center experience with median follow-up of 2.8 years

External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers

Current and future applications of machine and deep learning in urology: a review of the literature on urolithiasis, renal cell carcinoma, and bladder and prostate cancer

Is remote live urologic surgery a reality? Evidences from a systematic review of the literature

An updated meta-analysis of prostatic arterial embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia